methacetin
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
4
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00244569)
Timeline
Indications
Mechanism of action
- LiverRadiopharmaceutical
Liver radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 13-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 13c-methacetin
- methacetin
- methacetin
- methacetin
- methacetin, 14c-labeled
- n-(4-methoxyphenyl)acetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02786836 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2016 | Exalenz Bioscience LTD., Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The University of Texas, Dallas, University of Michigan |
| NCT01785082 | Phase 3 | Jan 1, 2013 | Humedics GmbH |
| NCT01205074 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2010 | Exalenz Bioscience LTD., Hebrew University |
| NCT00244569 | Phase 3 | Sep 1, 2005 | Oridion, Virginia Commonwealth University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exalenz Bioscience LTD. | For profit | 2 | 0 | 1 | 2010 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Humedics GmbH | For profit | 1 | 1 | 1 | 2013 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2016 |
| Oridion | For profit | 1 | 0 | 1 | 2005 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 1 | 1 | 2005 |
9 organizations
Page 1 / 1